COMPARISON: CAGRILINTIDE vs TIRZEPATIDE
Cagrilintide vs Tirzepatide: Key Differences
Amylin analog vs dual GIP/GLP-1 agonist
Cagrilintide vs tirzepatide compares two very different approaches to metabolic health — a single amylin pathway versus a dual incretin pathway, with different approval status.
At a Glance
| Cagrilintide | Tirzepatide | |
|---|---|---|
| Class | Amylin analog | Dual GIP + GLP-1 agonist |
| Pathways | Amylin/calcitonin | GIP and GLP-1 |
| Approval | Investigational | FDA-approved (Mounjaro, Zepbound) |
| Approved use | None yet | Type 2 diabetes; chronic weight management |
| Common effects | Mostly GI (trials) | Mostly GI |
Single vs Dual Pathway
Cagrilintide works through the amylin pathway; tirzepatide activates two incretin receptors (GIP and GLP-1). They are different mechanisms addressing overlapping goals.
Source: FDA Zepbound/Mounjaro labeling; Novo Nordisk cagrilintide program reporting.
The Status Difference
Tirzepatide is FDA-approved for defined uses; cagrilintide remains investigational.
Frequently Asked Questions
Is cagrilintide the same class as tirzepatide?
No. Cagrilintide is an amylin analog; tirzepatide is a dual GIP/GLP-1 agonist.
Which is FDA-approved?
Tirzepatide. Cagrilintide is investigational.
The Bottom Line
Cagrilintide vs tirzepatide is a single amylin pathway versus a dual incretin pathway, and investigational versus approved.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA Zepbound/Mounjaro (tirzepatide) labeling
- Novo Nordisk cagrilintide program reporting
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →